[{"id":"cb81a7f0-6230-4db7-aec3-4ce329f6c3b1","acronym":"FAME","url":"https://clinicaltrials.gov/study/NCT03709147","created_at":"2021-01-18T18:11:04.899Z","updated_at":"2024-07-02T16:36:38.650Z","phase":"Phase 2","brief_title":"Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma","source_id_and_acronym":"NCT03709147 - FAME","lead_sponsor":"Marina Garassino","biomarkers":" ALK • ROS1 • STK11 • IGF1","pipe":" | ","alterations":" PD-L1 overexpression • ALK rearrangement • ROS1 rearrangement • STK11 expression","tags":["ALK • ROS1 • STK11 • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression • ALK rearrangement • ROS1 rearrangement • STK11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 09/10/2023","primary_completion_date":" 09/10/2023","study_txt":" Completion: 09/10/2023","study_completion_date":" 09/10/2023","last_update_posted":"2020-11-16"}]